The problem with shorting overpriced bioteks is that they often are "story stocks", and any meaningful or meaningless story sends the shorts for cover. Safer bets are the like of QCOM, IBM and SBUX with deteriorating charts and no major expectations of "stories".
Market Data 
Markets 
AI
